A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT ID: NCT04482270
Last Updated: 2024-10-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
26 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-09-02
Study Completion Date
2021-03-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of fezolinetant and ES259564 (fezolinetant metabolite) in female participants with mild and moderate hepatic impairment compared to healthy female participants with normal hepatic function.
This study will also evaluate the safety and tolerability of a single oral dose of fezolinetant in female participants with mild and moderate hepatic impairment and healthy female participants with normal hepatic function.
This study will also evaluate the safety and tolerability of a single oral dose of fezolinetant in female participants with mild and moderate hepatic impairment and healthy female participants with normal hepatic function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function
NCT04476849
Healthy Volunteers
Renal Impairment
COMPLETED
PHASE1
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
NCT03983161
Healthy Volunteers
Hepatic Impairment
COMPLETED
PHASE1
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942
Hepatic Impairment
COMPLETED
PHASE1
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
NCT04252417
Healthy Volunteers
Hepatic Impairment of Moderate Child Pugh Category
TERMINATED
PHASE1
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061
Hepatic Impairment
Healthy Volunteers
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will comprise of three groups based on hepatic function. Participants will be screened for up to 28 days prior to investigational product (IP) administration on Day 1. Eligible participants will be admitted to the clinical unit on Day -1 and will be residential for a single period of six days/five nights. On Day 1, participants will receive a single oral dose of fezolinetant under fasting conditions followed by a 96-hour in-house blood and urine sampling period. Participants are to remain semirecumbent for four hours postdose. Standard safety and tolerability assessments will be conducted. Participants will be discharged from the clinical unit on Day 5 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit.
The study will be completed with an end-of-study visit (ESV). The ESV will take place five to nine days after the last pharmacokinetic sample is collected or at the time of early discontinuation from the study.
The study will be completed with an end-of-study visit (ESV). The ESV will take place five to nine days after the last pharmacokinetic sample is collected or at the time of early discontinuation from the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatic Impairment
Healthy Volunteers
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fezolinetant: Mild Hepatic Impairment
Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
Group Type
EXPERIMENTAL
fezolinetant
Intervention Type
DRUG
Oral
Fezolinetant: Moderate Hepatic Impairment
Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
Group Type
EXPERIMENTAL
fezolinetant
Intervention Type
DRUG
Oral
Fezolinetant: Normal Hepatic Function
Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
Group Type
EXPERIMENTAL
fezolinetant
Intervention Type
DRUG
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fezolinetant
Oral
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
ESN364
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a Body Mass Index (BMI) range of 18.5 to 36.0 kg/m\^2, inclusive and weighs at least 50 kg at screening.
* Female subject is not pregnant and at least one of the following conditions apply:
* Not a woman of childbearing potential (WOCBP)
* WOCBP who agrees to follow the contraceptive guidance for at least 30 days prior to day -1 through at least 30 days after IP administration.
* Female subject must agree not to breastfeed starting at screening and throughout the study period and for 30 days after IP administration.
* Female subject must not donate ova starting at first dose of IP and throughout the study period and for 30 days after IP administration.
* Subject agrees not to participate in another interventional study while participating in the present study.
Additional Criterion for Subjects with Hepatic Impairment:
* Subject has mild (Child-Pugh classification Class A, score 5 or 6) or moderate (Child-Pugh classification Class B, score 7 to 9) hepatic impairment.
* Female subject is not pregnant and at least one of the following conditions apply:
* Not a woman of childbearing potential (WOCBP)
* WOCBP who agrees to follow the contraceptive guidance for at least 30 days prior to day -1 through at least 30 days after IP administration.
* Female subject must agree not to breastfeed starting at screening and throughout the study period and for 30 days after IP administration.
* Female subject must not donate ova starting at first dose of IP and throughout the study period and for 30 days after IP administration.
* Subject agrees not to participate in another interventional study while participating in the present study.
Additional Criterion for Subjects with Hepatic Impairment:
* Subject has mild (Child-Pugh classification Class A, score 5 or 6) or moderate (Child-Pugh classification Class B, score 7 to 9) hepatic impairment.
Exclusion Criteria
* Subject has received any investigational therapy within 28 days or five half-lives, whichever is longer, prior to Day -1.
* Subject has any condition which makes the subject unsuitable for study participation.
* Female subject who has been pregnant within six months prior to screening or breastfeeding within three months prior to screening.
* Subject has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.
* Subject has had previous exposure with fezolinetant.
* Subject has used any inducer of cytochrome P450 (CYP) 1A2 in the three months prior or inhibitors of CYP 1A2 in the two weeks or five half-lives of the inhibitor, whichever is longer, prior to Day -1.
* Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration.
* Subject has/had febrile illness or symptomatic, viral (excluding chronic hepatitis B and C), bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within one week prior to Day -1.
* Subject has smoked, used tobacco-containing products and nicotine or nicotine-containing products (e.g., electronic vapes) within six months prior to screening or the subject tests positive for cotinine at screening or on Day -1.
* Subject has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within seven days prior to Day -1 and/or received a transfusion of any blood or blood products within 60 days.
* Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.
* Subject has creatinine level outside normal limits on Day -1. In such a case, the assessment may be repeated once.
Additional Criteria for Subjects with Hepatic Impairment:
* Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, immunologic, metabolic, dermatologic, psychiatric, renal and/or other major disease or malignancy, not related to current disease state.
* Subject has a history of consuming \> 7 units of alcoholic beverages per week within three months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within one year prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
* Subject has a mean pulse \< 45 or \> 90 beats per minute (bpm); mean systolic blood pressure (SBP) \> 160 millimeters of mercury (mmHg); mean diastolic blood pressure (DBP) \> 100 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
* Subject has a mean corrected QT interval using Fridericia's formula (QTcF) of \> 480 millisecond (msec) on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate electrocardiogram (ECG) may be taken.
* Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or on Day -1, unless the positive test is due to prescription drug use that is approved by the principal investigator and sponsor.
* Subject has a positive serology test for hepatitis A virus (HAV) antibodies (immunoglobulin M \[IgM\]) or antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at screening.
* Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period (e.g., advanced ascites, infection of ascites, fever, active gastrointestinal bleeding).
* Subject who has had a change in dose regimen of medically required medication(s) in the two weeks prior to screening (permitted concomitant medications) and/or subject for whom dose changes are likely to occur during the study (minor dose changes are allowed in agreement with the sponsor) and/or subject has used nonpermitted concomitant medication(s) in the three weeks prior to admission to the clinical unit (nonpermitted concomitant medications include any known hepatic enzyme-altering agents or compounds known to restrict metabolism, vitamins, hormonal contraceptives, hormone replacement therapy \[HRT\] and natural and herbal remedies, e.g., St. John's Wort).
* Subject has a presence of a hepatocellular carcinoma, or an acute liver disease caused by an infection or drug toxicity.
* Subject has severe portal hypertension or surgical portosystemic shunts, including transjugular intrahepatic portosystemic shunt.
* Subject has biliary liver cirrhosis, biliary obstruction or other cause of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
* Subject has signs of significant hepatic encephalopathy (hepatic encephalopathy Grade ≥ 2).
* Subject has severe ascites and/or pleural effusion.
* Subject has esophageal/gastric variceal bleeding in the past six months prior to screening, unless banded.
* Subject has thrombocyte level below 40 × 10\^9 per liter and /or hemoglobin \< 90 grams per liter.
* Subject has previous liver transplantation.
Additional Criteria for Healthy Subjects with Normal Hepatic Function:
* Subject has any of the liver function tests (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and total bilirubin \[TBL\]) ≥ 1.5 × the Upper Limit of Normal (ULN) or international normalized ratio (INR) \> 1.1 on Day -1. In such a case, the assessment may be repeated once.
* Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
* Subject has a history of consuming \> 7 units of alcoholic beverages per week within six months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within two years prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
* Subject has any clinically significant abnormality following the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on Day -1.
* Subject has a mean pulse \< 45 or \> 90 bpm; mean SBP \> 140 mmHg; mean DBP \> 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
* Subject has a mean QTcF of \> 450 msec on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate ECG may be taken.
* Subject has used any prescribed or nonprescribed drugs (including vitamins, hormonal contraceptives, HRT and natural and herbal remedies, e.g., St. John's Wort) in the two weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) and topical dermatological products, including corticosteroid products.
* Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or on Day -1.
* Subject has a positive serology test for HAV antibodies (IgM), hepatitis B surface antigen, hepatitis C virus antibodies or antibodies to HIV type 1 and/or type 2 at screening.
* Subject has any condition which makes the subject unsuitable for study participation.
* Female subject who has been pregnant within six months prior to screening or breastfeeding within three months prior to screening.
* Subject has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.
* Subject has had previous exposure with fezolinetant.
* Subject has used any inducer of cytochrome P450 (CYP) 1A2 in the three months prior or inhibitors of CYP 1A2 in the two weeks or five half-lives of the inhibitor, whichever is longer, prior to Day -1.
* Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration.
* Subject has/had febrile illness or symptomatic, viral (excluding chronic hepatitis B and C), bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within one week prior to Day -1.
* Subject has smoked, used tobacco-containing products and nicotine or nicotine-containing products (e.g., electronic vapes) within six months prior to screening or the subject tests positive for cotinine at screening or on Day -1.
* Subject has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within seven days prior to Day -1 and/or received a transfusion of any blood or blood products within 60 days.
* Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.
* Subject has creatinine level outside normal limits on Day -1. In such a case, the assessment may be repeated once.
Additional Criteria for Subjects with Hepatic Impairment:
* Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, immunologic, metabolic, dermatologic, psychiatric, renal and/or other major disease or malignancy, not related to current disease state.
* Subject has a history of consuming \> 7 units of alcoholic beverages per week within three months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within one year prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
* Subject has a mean pulse \< 45 or \> 90 beats per minute (bpm); mean systolic blood pressure (SBP) \> 160 millimeters of mercury (mmHg); mean diastolic blood pressure (DBP) \> 100 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
* Subject has a mean corrected QT interval using Fridericia's formula (QTcF) of \> 480 millisecond (msec) on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate electrocardiogram (ECG) may be taken.
* Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or on Day -1, unless the positive test is due to prescription drug use that is approved by the principal investigator and sponsor.
* Subject has a positive serology test for hepatitis A virus (HAV) antibodies (immunoglobulin M \[IgM\]) or antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at screening.
* Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period (e.g., advanced ascites, infection of ascites, fever, active gastrointestinal bleeding).
* Subject who has had a change in dose regimen of medically required medication(s) in the two weeks prior to screening (permitted concomitant medications) and/or subject for whom dose changes are likely to occur during the study (minor dose changes are allowed in agreement with the sponsor) and/or subject has used nonpermitted concomitant medication(s) in the three weeks prior to admission to the clinical unit (nonpermitted concomitant medications include any known hepatic enzyme-altering agents or compounds known to restrict metabolism, vitamins, hormonal contraceptives, hormone replacement therapy \[HRT\] and natural and herbal remedies, e.g., St. John's Wort).
* Subject has a presence of a hepatocellular carcinoma, or an acute liver disease caused by an infection or drug toxicity.
* Subject has severe portal hypertension or surgical portosystemic shunts, including transjugular intrahepatic portosystemic shunt.
* Subject has biliary liver cirrhosis, biliary obstruction or other cause of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
* Subject has signs of significant hepatic encephalopathy (hepatic encephalopathy Grade ≥ 2).
* Subject has severe ascites and/or pleural effusion.
* Subject has esophageal/gastric variceal bleeding in the past six months prior to screening, unless banded.
* Subject has thrombocyte level below 40 × 10\^9 per liter and /or hemoglobin \< 90 grams per liter.
* Subject has previous liver transplantation.
Additional Criteria for Healthy Subjects with Normal Hepatic Function:
* Subject has any of the liver function tests (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and total bilirubin \[TBL\]) ≥ 1.5 × the Upper Limit of Normal (ULN) or international normalized ratio (INR) \> 1.1 on Day -1. In such a case, the assessment may be repeated once.
* Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
* Subject has a history of consuming \> 7 units of alcoholic beverages per week within six months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within two years prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
* Subject has any clinically significant abnormality following the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on Day -1.
* Subject has a mean pulse \< 45 or \> 90 bpm; mean SBP \> 140 mmHg; mean DBP \> 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
* Subject has a mean QTcF of \> 450 msec on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate ECG may be taken.
* Subject has used any prescribed or nonprescribed drugs (including vitamins, hormonal contraceptives, HRT and natural and herbal remedies, e.g., St. John's Wort) in the two weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) and topical dermatological products, including corticosteroid products.
* Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or on Day -1.
* Subject has a positive serology test for HAV antibodies (IgM), hepatitis B surface antigen, hepatitis C virus antibodies or antibodies to HIV type 1 and/or type 2 at screening.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Global Development, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Executive Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States
Site Status
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States
Site Status
Orlando Clinical Research Center
Orlando, Florida, United States
Site Status
American Research Corporation
San Antonio, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2693-CL-0007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function
NCT05718258
COMPLETED
PHASE1
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
NCT04643795
COMPLETED
PHASE1
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
NCT01594957
COMPLETED
PHASE1
Pharmacokinetics Study in Patients With Impaired Hepatic Function
NCT02586194
COMPLETED
PHASE1
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115
COMPLETED
PHASE1
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
NCT05814926
COMPLETED
PHASE1
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
NCT04960124
COMPLETED
PHASE1
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
NCT01901133
COMPLETED
PHASE1
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
NCT03824678
COMPLETED
PHASE1
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
NCT02857868
COMPLETED
PHASE1
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
NCT06813781
COMPLETED
PHASE1
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
NCT06576765
COMPLETED
PHASE1
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
NCT03423446
COMPLETED
PHASE1
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
NCT01012284
COMPLETED
PHASE1
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622
COMPLETED
PHASE1
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
NCT02388620
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT02524717
COMPLETED
PHASE1
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
NCT06908954
RECRUITING
PHASE1
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
NCT04859426
COMPLETED
PHASE1
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528
COMPLETED
PHASE1
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
NCT02683577
COMPLETED
PHASE1
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
NCT05093972
NOT_YET_RECRUITING
PHASE1
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
NCT04276662
COMPLETED
PHASE1
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234
COMPLETED
PHASE1
A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
NCT01197911
COMPLETED
PHASE1